Home » Stocks » RAIN

Rain Therapeutics, Inc. (RAIN)

Stock Price: $16.74 USD -0.72 (-4.12%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 434.46M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 25.95M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $16.74
Previous Close $17.46
Change ($) -0.72
Change (%) -4.12%
Day's Open 17.22
Day's Range 16.51 - 17.22
Day's Volume 64,106
52-Week Range 14.08 - 23.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021

1 month ago - GlobeNewsWire

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, ...

1 month ago - GlobeNewsWire

Completed initial public offering ("IPO") with net proceeds of $121.9 million

2 months ago - GlobeNewsWire

Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer

2 months ago - GlobeNewsWire

NEWARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public...

3 months ago - GlobeNewsWire

The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.

3 months ago - BioSpace

A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.

3 months ago - EndPoints News

Rain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About RAIN

Rain Therapeutics is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 23, 2021
CEO
Avanish Vellanki
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
RAIN
Full Company Profile

Financial Performance

Financial Statements